Skip to main content
. 2023 Jan 20;6(2):306–319. doi: 10.1021/acsptsci.2c00223

Figure 4.

Figure 4

Deletion of c-jun in Schwann cells does not abrogate drug efficacy. (A) Grip strength data for mice treated with 1 mg/kg cemdomespib beginning at 4 months of age are shown as mean ± SD and were analyzed using a three-way mixed effects model and Tukey’s test (n = 4–6 per treatment). *, p < 0.0001 versus the time-matched vehicle-treated genotype control. #, p < 0.0001 versus time-matched Cx32def vehicle treated. (B) For each genotype, grip strength in the cemdomespib-treated mice was normalized to the average grip strength of the time-matched, vehicle-treated controls. Data are mean ± SD and were analyzed using a two-way mixed effects model and Sidak’s test *, p < 0.009 versus time-matched Cx32def. (C) Cemdomespib therapy improved MNCV in each of the genotypes. Data are mean ± SD and were analyzed using a one-way ANOVA and Sidak’s test. Symbols indicate the response of individual animals in each group.